Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Trial details
- Registry ID
- NCT04773600
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)NCT04773600 | ARQT | Phase 3 | Completed | 2022-09-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |